Literature DB >> 1972445

Low-dose regimen of interleukin-2 for metastatic renal carcinoma.

D T Sleijfer, R A Janssen, P H Willemse, A Martens, L de Leij, E G de Vries, N H Mulder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1972445     DOI： 10.1016/0140-6736(90)93057-v

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.

Authors:  R A Janssen; J Buter; E Straatsma; A A Heijn; D T Sleijfer; E G de Vries; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 2.  The immunobiological effects of interleukin-2 in vivo.

Authors:  R A Janssen; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

3.  Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.

Authors:  R A Janssen; D T Sleijfer; A A Heijn; N H Mulder; T H The; L de Leij
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

4.  Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.

Authors:  A Martens; R A Janssen; D T Sleijfer; A A Heijn; N H Mulder; T H The; L de Leij
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.